Source | Pain | Disability | Joint Swelling/tenderness | Patient Global |
---|---|---|---|---|
Merck Sharp & Dohme | Likert 0–4 | NA | Likert 0–3* | Response to treatment (Likert 0–4 point) |
Pfizer | Likert 0–4 | NA | Likert 0–3* | Response to treatment (Likert 0–4 point) |
Regeneron | Likert 0–4, NRS 0–10 | Activity limitations, NRS 0–10 (from WPAI:SHP v2.0) | NA† | No measure† available |
Novartis | Likert 0–4, VAS 0–100 | HAQ-DI | Likert 0–3* | Response to treatment (Likert 0–4 point) |
Auckland University of Technology | VAS 0–100 | HAQ-II | Swollen and tender joint count | VAS 0–100 |
↵* Index joint assessed by a physician;
↵† Likert 0–3 grade for joint tenderness and swelling was used in the actual trial but those data were not available for the current analysis. NA: no measure available; HAQ-II: Health Assessment Questionnaire version II; HAQ-DI: Health Assessment Questionnaire Disability Index; VAS: visual analog scale; WPAI:SHP: Worker Productivity and Activity Impairment Index (Specific Health Problem)9; NRS: numeric rating scale.